Document:

Joint Development Agreement

 EXHIBIT 10.30 
 JOINT DEVELOPMENT AGREEMENT 
 This JOINT DEVELOPMENT AGREEMENT (the
“Agreement”) is entered into by MiMedx, Inc., a Florida corporation, having a principal place of business located at 1234 Airport Road, Suite 105, Destin, FL 32541 (“MiMedx”) and Offray Specialty Narrow
Fabrics, Inc., a New York corporation having a principal place of business located at 360 Route 24, P.O. Box 421, Chester, NJ 07930-0421 (“Offray”) (with MiMedx and Offray hereinafter collectively referred to as
the “Parties,” each a “Party”). 
 RECITALS 
 WHEREAS, MiMedx has technical expertise in producing NDGA-treated collagen fibers suitable for medical implants, such as braided
or woven collagen implants, and owns or has exclusive rights to patents and patent applications covering NDGA-treated collagen and implants; 
 WHEREAS, Offray has technical expertise in woven textile production and manufacturing; and 
 WHEREAS, the Parties desire to collaborate to jointly develop commercial production processes for fabricating woven and/or braided NDGA-treated collagen fiber bioprostheses. 
 NOW, THEREFORE, in consideration of the foregoing and such other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the Parties, intending to be legally bound, agree and covenant as follows: 
 AGREEMENT 
  

	1.	 DEVELOPMENT ACTIVITIES 

 1.1 Development Activities; Defined. 
 The Parties shall cooperate and use all
reasonable diligence to: (i) jointly research and develop, for a period of one (1) year from the date of the last signature to this Agreement (the “Effective Date”), commercial production processes and equipment for
fabricating woven and/or braided NDGA-treated collagen fibers into bioprostheses (the “First Phase”); and (ii), upon successful completion of the First Phase, the Parties shall cooperate to develop, for a period of eighteen
(18) months after completion of the First Phase, a manufacturing process that reliably 

  

 - 1 - 

 
produces at least one (1) woven NDGA-treated collagen fiber bioprosthesis and which, as determined and mutually agreed upon by the Parties in
writing, is suitable for commercial medical product production (collectively, the “Second Phase”) (with (i) and (ii) collectively referred to as the “Development Activities”). 
 1.2 First Phase. 
 Offray shall perform feasibility testing by weaving MiMedx collagen fibers at Offray’s Watsontown, Pennsylvania facility (the “Watsontown Facility”). The Parties recognize that successful testing
conducted during the First Phase may require multiple fabrication and/or test iterations. MiMedx shall evaluate whether the feasibility testing conducted during the First Phase is successful using its own material testing and validation of a
woven collagen fiber product made by Offray, and may, upon prior written notice to, and the prior written consent of, Offray, which consent shall not be unreasonably withheld, conduct an audit of Offray’s Watsontown
Facility and the work conducted by Offray during the First Phase, including all laboratory notebooks, equipment and prototypes made to arrive at any tested specimens developed as part thereof. 
 1.3 Offray Employees. 
 Offray agrees that each employee and consultant who performs any services in any way relating to the First Phase or Second Phase (as defined below) shall be appropriately informed of the terms of this
Agreement, and that each such employee and consultant shall be under legal obligation to Offray by contract or otherwise sufficient to impose on such employee or consultant a legal obligation to comply with the terms and conditions of
this Agreement, including, without limitation, the confidentiality obligations of Section 8 of this Agreement, and, for each employee, consultant or consultant’s entity for individuals that may be an inventor, a legal
obligation to assign to Offray all rights to and in all intellectual property, including, without limitation, all inventions, copyrights, patents and trademarks, created by such employee or consultant during their employment by or with
Offray. 
 1.4 Second Phase. 
 Upon successful completion of the First Phase, as determined by MiMedx in its sole discretion, the Parties shall cooperate and use all reasonable diligence to conduct the Second
Phase. During the Second Phase, MiMedx scientists shall travel to Offray’s Watsontown Facility at MiMedx’s expense and assist as needed for the design and development of the 

  

 - 2 - 

 
manufacturing process to be developed during the Second Phase. During the Second Phase, and upon Offray’s request, MiMedx shall assist
Offray in analyzing any prototype bioprosthesis products. Notwithstanding the foregoing, MiMedx may, at its sole discretion, request a sample woven bioprosthesis product produced by Offray in order to conduct its own material
testing and validation of any such woven bioprosthesis product produced by Offray during the Second Phase, MiMedx will use all reasonable efforts to promptly return any test analysis of prototypes of woven bioprosthesis products within
two (2) weeks of receipt of any such materials and/or products to be tested, unless agreed otherwise by the Parties. During the Second Phase, MiMedx may, upon prior written notice to, and the prior written consent of,
Offray, which consent shall not be unreasonably withheld, perform an onsite quality control, manufacturing and regulatory audit of the Watsontown Facility to assess compliance with the United States Food and Drug Administration guidelines or
other similar foreign regulatory authority. 
 1.5 Monthly Evaluation and Reporting. 
 During the First and Second Phase, the Parties shall communicate with each other at least monthly to evaluate ongoing Development
Activities. Offray shall also provide bi-monthly progress reports regarding the status and progress of the First Phase and, if initiated, the Second Phase. The progress reports shall include a brief written review of the work performed during
the previous two (2) weeks containing the following: (i) a summary of the work performed on the Development Activities; (ii) an overview of any progress made towards completion of the First or Second Phase, as the case may be; and
(iii) recommendations for any proposed alterations in or to the Development Activities. MiMedx shall review each progress report and provide any response to Offray in writing within one (1) week of MiMedx’s
receipt thereof. Notwithstanding the foregoing, the Parties, may, if mutually agreed upon, also routinely confer with regard to the Development Activities in-person or by telephone. 
 1.6 Salaries of Employees. 
 All salaries, benefits, and insurance in any way relating to this Agreement, including, without limitation, any work performed on the Development Activities, shall be paid by each Party for its own
employees. Any overtime hours expended, or additional staff hired, by a Party for the purposes of this Agreement, including, without limitation, any work performed on the Development Activities, shall be paid by each Party with
no cost, obligation, or liability to the other Party. 
  

 - 3 - 

 1.7 Manufacturing and Supply Agreement. 
 If the First and Second Phase of the Development Activities are successful, as mutually agreed upon by the Parties, MiMedx
agrees to consider Offray as a potential commercial supplier if Offray is able to demonstrate that it can meet or exceed reasonable and customary United States medical supplier standards for delivery, manufacturing capacity,
competitive cost and ability to meet all quality and manufacturing regulatory requirements. 
  

	2.	 MIMEDX SUPPORT AND PAYMENTS 

 2.1 Equipment. 
 In support of the First Phase, MiMedx shall purchase a handloom of
Offray’s choosing with a cost not to exceed $4,000 (US). This and any other equipment purchased by MiMedx for use in the Development Activities shall be owned by MiMedx and, upon request, returned to MiMedx,
regardless of the outcome of the Development Activities, unless each Party agrees otherwise in writing. MiMedx shall not be obligated to pay for any other equipment used in the Development Activities unless approved by MiMedx in
advance in writing. 
 2.2 Payment for Development Activities. 
 In addition to the royalty payments set forth in Section 3.4, MiMedx shall pay Offray for the First Phase in accordance
with the Fee Schedule dated June 18, 2007 (not to exceed $15,200 US, without prior written consent of MiMedx) between the Parties, attached hereto as Exhibit A. If the first Phase is successful and MiMedx decides to pursue
the Second Phase, the Parties shall mutually agree upon reimbursement of and/or payment for reasonable expenses to be paid to Offray for the Second Phase, such Agreement to be in wring and signed by the Party to be
charged. 
 2.3 Supply of Collagen Fibers/Assistance. 
 MiMedx shall supply Offray with NDGA-treated collagen fibers or NDGA to treat collagen fibers to be used in the Development Activities in reasonable amounts and meeting appropriate
product specifications as necessary to properly conduct the Development Activities, and shall provide technical assistance to Offray with regard to the Development Activities as reasonably requested by Offray. 
 2.4 Travel and travel costs. 
 MiMedx shall, upon proper documentation provide by Offray, refund or reimburse Offray for all reasonable travel costs, including, without limitation, coach class airfare and 

  

 - 4 - 

 
reasonable living (i.e. room and board) expenses, for Offray employees and consultants who, at the request of MiMedx, travel to
MiMedx’s Destin, Florida location or other specified location for meetings relating in any way to the Development Activities. 
  

	3.	 OWNERSHIP OF INTELLECTUAL PROPERTY 

 3.1 Definitions. 
 For purposes of this Agreement: 
 (a) “Intellectual Property” means any and all intellectual property, including, but not limited to, inventions,
copyrights, copyright applications or registrations, original works of authorship, developments, improvements, patents, patent applications, Patent Rights (as defined in Section 3.1(e)) trademarks, trademark applications, trade names, trade
secrets, designs, technical information, formulations, processes, know-how, data, specifications, test results, drawings, manufacturing equipment and other information, whether or not patented or patentable, or otherwise subject to protection under
any applicable laws, rules and regulations, which in any way relate to, or arise from, this Agreement, including, without limitation, the Development Activities. 
 (b) “Joint Intellectual Property” means Intellectual Property having at least one (1) co-creator who is an
employee, agent, servant, representative or consultant of Offray and one co-creator who is an employee, agent, servant, representative or consultant of MiMedx. 
 (c) “MiMedx Intellectual Property” means Intellectual Property having as creators only employees, agents,
servants, representatives or consultants of MiMedx. 
 (d) “Offray Intellectual
Property” means Intellectual Property having as creators only employees, agents, servants, representatives or consultants of Offray. 
 (e) “Patent Rights” means all rights under any patent or patent application in any country, including any substitution, extension or supplementary protection certificate, reissue,
reexamination, renewal, division, continuation or continuations-in-part thereof which in any way relate to, or arise from, this Agreement, including, without limitation, the Development Activities. “Joint 

  

 - 5 - 

 
Patent” means any patent from the Patent Rights that is jointly owned such that the patent has at least one inventor who is an employee, agent, servant,
representative or consultant of Offray and at least one inventor who is an employee, agent, servant, representative or consultant of MiMedx. “Offray Patent” means any patent from the Patent Rights with all inventors
being only employees, agents, servants, representatives or consultants of Offray. “MiMedx Patent’ means any patent from the Patent Rights with all inventors being only employees, agents, servants, representatives or
consultants of MiMedx. 
 3.2 Ownership of Joint Intellectual Property/Royalty. 
 MiMedx and Offray shall jointly own all Joint Intellectual Property. 
 3.3 Ownership of MiMedx Intellectual Property. 
 MiMedx shall own all MiMedx Intellectual Property. 
 3.4
Ownership of Offray Intellectual Property/Royalty/License. 
 Offray shall own all Offray Intellectual
Property. 
 Offray hereby grants to MiMedx an exclusive, irrevocable, right and license, with the right to
sublicense the Offray Intellectual Property and the Joint Intellectual Property, including the right to use or have used, make or have made, market, have marketed, offer for sale, import for sale, and sell and have sold any product of process
covered by Offray Patent(s) and/or any Joint Patent(s) in the field of medical collagen bioprosthesis (the Field). 
 MiMedx hereby covenants and agrees to pay Offray a two percent (2%) royalty on gross sales revenues of any products covered by or products produced by processes covered by an Offray Patent. MiMedx hereby
covenants and agrees to pay a 1 percent (1%) royalty on gross sales revenues of any products covered by or products produced by processes covered by a Joint Patent. However, to be clear, no multiple royalties shall be due or payable because any
product and/or method to produce such product is covered by or more than one Offray Patent and/or Joint Patent. For example, in the situation where a product and/or method to produce such product is covered by both at least one Offray
Patent(s) and at least one Joint Patent(s) or two or more Offray Patents, the royalty due shall still remain at 2% and in the situation where a product and/or method to produce such product is covered by one or more Jointly Owned Patents, the
royalty due shall be 1%. Terms for payment of and accountability for sales will be defined by a later drafted Agreement should a Joint Patent(s) or Offray Patent issue and the Parties agree to 

  

 - 6 - 

 
act in good faith to establish such implementing details and definitions as reasonable and customary. 
 3.5 Patent Prosecution and Maintenance. 
 MiMedx shall, at its sole discretion, have the right, but not the obligation, to prepare, file prosecute and maintain at its own expense any patent applications and/or patents relating to the Joint Intellectual
Property. If, after ninety (90) days written notice from either Party to the other Party that there exists Joint Intellectual Property that a Party reasonably believes should be protected, MiMedx declines to fund or
prepare and file a patent application relating thereto, then Offray shall have the right, at Offrays expense, to prepare, file, prosecute and maintain any patent application(s) relating to such Joint Intellectual Property. If
MiMedx declines to fund and Offray decides to do so for a particular Joint Patent, then the exclusive license under Section 3.4 converts to a non-exclusive license for that Joint Patent. 
 Each Party shall be responsible for protecting any Intellectual Property solely owned by that Party, unless agreed
otherwise in writing. 
 3.6 Laboratory Notebooks. 
 Each Party agrees to use its reasonable efforts to have its employees and/or consultants timely and promptly record, date and witness any and all Intellectual Property in bound laboratory
notebooks. Intellectual Property shall be disclosed and reported to the other Party within thirty (30) days of the date indicated for the same in the laboratory notebook. 
  

	4.	 INFRINGEMENT OF INTELLECTUAL PROPERTY 

 4.1 Notice of Infringement. 
 Upon becoming aware of any alleged infringement of Intellectual
Property, each Party shall promptly notify the other Party of any and all available evidence of infringement, and the Parties shall cooperate to diligently investigate and determine, in the exercise of reasonable judgment and
good practice, whether the activities in question in fact constitute an infringement of Intellectual Property. The Parties shall promptly confer with respect to the strategy for responding to any alleged infringement, including, without
limitation, offers to license, declaratory judgments, or initiation and prosecution of civil litigation against any alleged infringer, or defense of a third Party infringement claim, as circumstances dictate. 
  

 - 7 - 

 4.2 Infringement of Joint Intellectual Property Rights. 
 MiMedx shall have the right, but not the obligation, to prepare, file, prosecute and maintain in any legal action for any alleged
infringement of Joint Intellectual Property, and Offray agrees that MiMedx may cause Offray to join any such action as a Party at the expense of MiMedx. All fees, costs and expenses of any legal action instituted
by MiMedx for infringement of Joint Intellectual Property shall be borne by MiMedx, Offray hereby covenants and agrees that it shall, at the request and expense of MiMedx, cooperate in all respects and, to the extent
possible, have its employees, consultants, officers and directors, testify when requested and make available relevant records, papers, information, samples, and specimens, as requested by MiMedx. MiMedx shall have the right to settle
any such litigation upon the consent of Offray, with such consent not to be unreasonably withheld, and Offray agrees to execute any documents necessary to effectuate any such settlement as requested by MiMedx. MiMedx
shall be solely entitled to any damages recovered from the settlement, suit or litigation. 
 If MiMedx declines to
file or maintain an infringement action relating to Joint Intellectual Property then Offray shall have the right to file and maintain any such action(s). In such instance, MiMedx and Offray shall share jointly in any recovery or
damages awarded in any such action on an equal percentage after Offray has been reimbursed in full for all fees, costs and expenses incurred in any such legal action. 
 Where MiMedx has declined to fund a Joint Patent under Section 3.5, then Offray shall have the right, but not the obligation, to prepare, file, prosecute and maintain any legal
action for any alleged infringement of the Joint Patent, and MiMedx agrees that Offray may cause MiMedx to join any such action as a Party at the expense of Offray. All fees, costs and expenses of any legal action
instituted by Offray for infringement of a Joint Patent shall be borne by Offray. Offray shall be solely entitled to any damages recovered from the settlement, suit or litigation. 
 4.3 Prosecution of MiMedx Intellectual Property Rights. 
 MiMedx shall have the right, but not the obligation, to file and maintain legal action for any infringement of MiMedx Intellectual Property, and Offray agrees that
MiMedx may cause Offray to join any such action as a Party at the expense of MiMedx. All fees, costs and expenses of any such legal action instituted by MiMedx for infringement of MiMedx Intellectual
Property shall be borne by MiMedx, and MiMedx shall retain any recovery or 

  

 - 8 - 

 
damages awarded in any such action. Offray hereby covenants and agrees that it shall, at the request and expense of MiMedx, cooperate in all
respects and, to the extent possible, have its employees, consultants, officers and directors, testify when requested and make available relevant records, papers, information, samples and specimens, as requested by MiMedx. MiMedx shall
have the right to settle any such litigation and Offray agrees to execute any documents necessary to effectuate any such settlement as requested by MiMedx. 
 4.4 Prosecution of Offray Intellectual Property Rights. 
 Offray shall have the right, but not the obligation, to file and maintain legal action for any infringement of Offray Intellectual Property, and MiMedx agrees that Offray may cause MiMedx to join any such
action as a Party at the expense of Offray. All fees, costs and expenses of any such legal action instituted by Offray for infringement of Offray Intellectual Property shall be borne by Offray, and Offray
shall retain any recovery or damages awarded in any such action. MiMedx hereby covenants and agrees that it shall, at the request and expense of Offray, cooperate in all respects and, to the extent possible, have its employees,
consultants, officers and directors, testify when requested and make available relevant records, papers, information, samples and specimens, as requested by Offray. Offray shall have the right to settle any such litigation and
MiMedx agrees to execute any documents necessary to effectuate any such settlement as requested by Offray. Notwithstanding the above, if Offray declines to file or maintain legal action for infringement of an Offray
Patent after requested to do so by MiMedx, then MiMedx will not owe any royalties for the Offray Patent involved. If Offray settles such legal action for an Offray Patent without MiMedx consent, then
MiMedx will not owe any royalties of the Offray Patent involved. 
 If Offray declines to take, file or
maintain legal action for infringement of Offray Intellectual Property, Offray agrees, upon receipt of written request of MiMedx to file or maintain such legal action for infringement of Offray Intellectual Property.
MiMedx shall agree to bear the costs for expenses and fees associated with such legal action. MiMedx shall retain any recovery, settlement or damages from such action. 
  

	5.	 JOINT RESEARCH AGREEMENT 

 The Parties stipulate, acknowledge and agree that this Agreement is a joint research Agreement for the performance of experimental, developmental or research work in the field of biomedical
collagen fiber bioprostheses and associated manufacturing methods under 35 U.S.C. 

  

 - 9 - 

 
§ 103(c)(3), and that Offray and MiMedx shall be treated as common owners for inventions in this field as provided for in the Cooperative
Research and Technology Enhancement Act of 2004. 
  

	6.	 TERM AND TERMINATION 

 This Agreement shall continue in effect for one (1) year from the Effective Date (the “Term”), unless terminated by either Party for any reason by giving thirty (30) days prior
written notice to the other Party. The Term of this Agreement may be renewed or extended annually for one (1) additional year by mutual consent and written Agreement of the Parties. 
  

	7.	 SURVIVAL OF PROVISIONS. 

 The terms and conditions of Sections 3, 4, 5 (for inventions arising from activities prior to the termination date), 8, and 9 of this Agreement shall survive the expiration or termination of this
Agreement. 
  

	8.	 CONFIDENTIALITY 

 8.1 Confidentiality. 
 Each Party acknowledges and agrees that during tile Term of this Agreement,
including any renewals and extensions thereof exercised by the Parties in accordance with Section 6 of this Agreement, each Party will have access to confidential and proprietary information of the other Party. In
recognition of the foregoing, each Party hereby covenants and agrees to and shall at all times, both during the Term of this Agreement, including any renewals and extensions thereof exercised by the Parties in accordance with
Section 6, and thereafter, hold and keep all Confidential Information (as defined in Section 8.2) in strict confidence and trust, and not use or disclose to any person, firm, corporation or other entity any Confidential Information which
it encounters, obtains, creates or develops other than as expressly permitted under the terms and conditions of this Agreement or unless consented to by the other Party in writing. Each Party hereby covenants and agrees that it
shall not disclose Confidential Information to any employee, servant, representative, agent or consultant of the Party, except to the extent that each such person or entity has a need for Confidential Information in order to perform any
services pursuant to this Agreement. Each Party hereby covenants and agrees that any of its employees, servants, representatives, agents and consultants who perform any services 

  

 - 10 - 

 
pursuant to this Agreement shall: (i) be notified of the confidential nature of this Agreement, including, without limitation, the
Development Activities, and the specific confidentiality obligations of this Section 8; (ii) agree to take reasonable efforts to hold and keep all Confidential Information in strict confidence and trust, and not disclose any Confidential
Information to any third Party; and (iii) be expressly bound by the terms and conditions of this Agreement, including, without limitation, the confidentiality provisions of this Section 8. 
 8.2 Confidential Information Defined. 
 For purposes of this Agreement, “Confidential Information” means any proprietary information, technical, business and financial data, trade secrets or know-how, including, but not limited to,
research, product plans, products, services, vendor lists, supplier lists and suppliers, customer lists and customers (including, but not limited to, customers of the Parties), contacts at or knowledge of clients or prospective clients of the
Parties, pricing information and costs, markets, software, ideas, concepts, developments, inventions, discoveries, protocols, scripts, features and modes of operation, interfaces, works of authorship, databases or database criteria,
algorithms, methodologies, processes, formulas, computer codes, technology, designs, drawings, internal documentation, engineering materials, hardware configuration information, marketing data, licenses, finances, budgets, projections, forecasts,
strategies, salaries, terms of compensation of other employees or other business information disclosed to any Party, either directly or indirectly, in writing, orally or by drawings or observation during the Term of this Agreement, and
any other materials of any nature relating to any matter within the scope of the business of the Parties or concerning any of the dealings or affairs of the Parties, including, without limitation, the Development Activities.

 8.3 Return of Confidential Information. 
 Upon request, each Party agrees to return to the other Party any written, printed or other materials embodying Confidential Information, including, without limitation, all copies or
excerpts thereof, given to or acquired by such Party in connection with this Agreement, including, without limitation, the Development Activities. Neither Party shall, directly or indirectly, disclose to the public or to any
non-essential person or entity any of the terms of this Agreement without the prior written consent of the other Party, unless otherwise required to do so by any law, rule and/or regulation established by any government or regulatory
agency with applicable jurisdiction. However, MiMedx shall be free to disclose the terms of the Agreement  

  

 - 11 - 

 
to potential investors, investors, business collaborators or potential collaborators and/or stock holders. 
 8.4 Remedies for Breach. 
 Each Party acknowledges that any breach of this Section 8 by one Party shall cause irreparable injury to the other Party not readily measurable in monetary amounts. Consequently, each
Party shall, without waiving any other rights or remedies be entitled to injunctive and/or declaratory relief in connection with any breach or threatened breach by a Party of the confidentiality obligations of this Section 8. Each
Party waives the requirement for the securing or posting of any bond in connection with such remedy. 
 8.5 Limitation
on confidential Information. 
 Neither of the Parties shall be bound by the obligations restricting use and disclosure
of any Confidential Information set forth in this Section 8 which: (i) was known by the receiving Party prior to disclosure, as evidenced by its business records; (ii) was lawfully in the public domain prior to its disclosure
or becomes publicly available other than through breach of this Agreement; (iii) was disclosed to the receiving Party by a third Party provided that such third Party is not in breach of any confidentiality obligation
in respect of such information; (iv) is independently developed by the receiving Party as evidenced by its business records; or (v) is disclosed when such disclosure is compelled pursuant to legal, judicial or administrative
proceeding or otherwise required by law subject to the receiving Party giving all reasonable prior notice to the disclosing Party to allow it to seek protective or other court orders. 
  

	9.	 INDEMNIFICATION 

 MiMedx shall indemnify and hold Offray, its employees and officers, directors and shareholders (collectively “the Indemnities”) harmless from and against any and all loss, damage, claim, obligation, liability, cost
and expense (including, without limitation, reasonable attorneys’ fees and costs and expenses incurred in investigating, preparing, defending against or prosecuting any litigation, claim, proceeding or demand), of any kind or character
resulting from any and all claims or actions for, patent infringement, or from any judgment entered therein, which may be brought against the Indemnities or any one of them as a result of their activities under this Agreement, including,
without limitation, the Development Activities (collectively, “Losses”). MiMedx agrees that any prototypes produced during the Development Activities are experimental will not be used for human clinical purposes. 
  

 - 12 - 

	10.	 OTHER MATTERS 

 10.1 Entire Agreement 
 The Parties stipulate, acknowledge and agree that this Agreement,
including any attachments hereto, constitutes the entire Agreement between the Parties with respect to the subject matter hereof, and supersedes and terminates any and all prior Agreements, requests for quotation, quotations,
purchase orders, letters of intent and understandings between the Parties, and any and all promises, statements, and representations made by either Party to the other concerning the subject matter hereof and the terms applicable
hereto. 
 10.2 Amendments 
 This Agreement may not be released, discharged, amended, or modified in any manner, except by an instrument in writing that references this Agreement and is signed by a duly authorized officer of each
Party. 
 10.3 Assignment. 
 This Agreement and the benefits and obligations hereunder may not be assigned by Offray without the prior written consent of MiMedx. MiMedx may assign this
Agreement and its obligations, benefits and rights under this Agreement. MiMedx shall provide written notice to Offray of such assignment. 
 10.4 Independent Contractors. 
 In making and performing this
Agreement, the Parties, and all agents, representatives, contractors and employees of the Parties, are acting and shall act at all times as independent contractors and nothing contained in this Agreement shall be
construed or implied to create an agency, partnership or joint venture relationship between the Parties. 
 10.5
Waiver. 
 The failure of either Party to insist upon the performance of any of the terms of this Agreement or
to exercise any right hereunder or at law or in equity, or any delay by either Party in the exercise of any such right, shall not be construed as a waiver or relinquishment of any such performance or right or of the future performance of any
such term or the future exercise of such right, and any effective waiver or relinquishment of any such right must be in writing and signed by a duly authorized officer of the Party waiving or relinquishing the right or rights. No waiver or
relinquishment of any right granted by either Party to the other shall be deemed to be a continuing waiver of such right in the future unless otherwise provided in the waiver. 
  

 - 13 - 

 10.6 Severability. 
 If any provision of this Agreement or the application of any provision of this Agreement to any Party or circumstance
is, to any extent, invalid or unenforceable, the application of the remainder of such provision to such Party or circumstance, the application of such provision to other persons, entities or circumstances, and the application of the remainder
of this Agreement will not be affected thereby. To the extent any provision of this Agreement is enforceable in part but not in whole, such provision shall be enforced to the maximum extent permitted by applicable law. If such
condition, covenant or other provision shall be deemed invalid due to its scope or breadth, such provision shall be deemed valid to the extent of the scope or breadth permitted by law. 
 10.7 Third-Party Beneficiaries. 
 The provisions of this Agreement are for the sole benefit of the Parties, and do not create any third party beneficiary rights in any other person or entity. 
 10.8 Further Assurances. 
 Each of the Parties shall execute and deliver to, or cause to be executed and delivered to, the other Party, such further instruments, or take such other actions as may reasonably be requested of it to
consummate more effectively the transactions contemplated hereby. 
 10.9 Expenses. 
 Each Party shall bear their respective expenses incurred or to be incurred in connection with the execution and delivery of this
Agreement. 
 10.10 Notices. 
 Any notice or other written communication required or permitted to be made or given hereunder may be made or given by either Party to the other Party by fax communication to the fax
number set forth below and such notice shall be followed up by depositing the same in the mail, certified delivery, return receipt requested, postage prepaid, and addressed to the mailing address set forth below: 
  

			
	 To Offray:
	  	 Offray Specialty Narrow Fabrics, Corp.
 360 Route 24 P.O. Box 421

		  	 Chester, NJ 07930-0421
 Att: Ralph Artigliere
 Facsimile: (908) 879-3630

  

 - 14 - 

			
	 With a copy to:
	  	 Sills Cummis Epstein & Gross P.C.
 One Riverfront Plaza
 Newark, NJ 07102
 Att: Leslie Restaino, Esq.
 Facsimile: (973) 643-6500
 Email: lrestaino@sillscurnmis.com

		
	 To MiMedx:
	  	 MiMedx, Inc.
 1234
Airport Road
 Suite 105 Destin, FL 32541
 Att: Maria Steele
 Facsimile: (850) 650-2213

		
	 With a copy to:
	  	 Myers, Bigel, Sibley & Sajovec, P.A.
 4140 Parklake Ave. Ste. 600
 Raleigh, NC 27612 Att: Julie Richardson, Esq.
 Facsimile: (919) 677-8872
 Email:
jrichardson@MyersBigel.com

 10.11 Governing Law. 
 This Agreement and the relationships and the relationship between the Parties created hereunder shall be governed by and
construed in accordance with the laws of the State of Delaware, without reference to choice of law doctrine. EACH PARTY HEREBY WAIVES TRIAL BY JURY WITH RESPECT TO ANY MATTER RELATING TO THIS AGREEMENT. 
 10.12 Force Majeure. 
 The untimely performance of any obligation arising under this Agreement by either Party will be excused, and such delay of performance shall not constitute a breach or grounds for termination or prejudice of any rights
hereunder, provided that (a) the delay of performance is a result of circumstances or occurrences beyond the reasonable control of the Party whose performance is excused hereunder (the “Delaying Event”), and (b) such
Party shall (i) immediately resume performance after the Delaying Event is removed and (ii) be reasonably diligent during such Delaying Event in avoiding further delay. Without limiting the generality of circumstances or occurrences
that shall constitute a Delaying Event, examples of Delaying Events include, but are not limited, strikes, shortages of power or other utility services, materials or transportation, acts of government or of God, sabotage, insurrection and civil war.
A Party 

  

 - 15 - 

 
whose performance may he affected by a Delaying Event shall promptly give notice to the other Party of such Delaying Event and the fact that it
intends to rely upon such Delaying Event to excuse its performance under this Agreement. 
 10.13 Publicity.

 No publication, advertising, or publicity matter having any reference to either MiMedx or Offray, expressed
or implied, shall be made use of by any Party, unless and until such matter shall have first been mutually agreed upon in writing by the other Party. 
 10.14 Construction. 
 The headings contained in this Agreement
are included for purposes of convenience only, and do not affect the meaning or interpretation of this Agreement. Any reference to the singular in this Agreement also includes the plural and vice versa. If the required date of
any action to be taken by a Party pursuant to this Agreement falls on a Saturday, Sunday or day in which banks in New Jersey are required to be closed (a “business Day”), such action shall be required to be taken on the first
Business Day following such date. 
 10.15 Binding Agreement/Successors. 
 All representations, covenants and Agreements contained in this Agreement by or on behalf of any of the Parties shall
be binding upon, and shall inure to the benefit of, the Parties and their respective Successors. For purposes of this Section, “Successors” means their representatives, estates, heirs, devisees, legatees, distributes, successors and
permitted assigns. 
 10.16 Mutual Drafting. 
 The Parties agree that for all purposes of this Agreement they shall be deemed to have participated jointly in the negotiation and drafting of this Agreement. If any
ambiguity or questions of intent or interpretation arises, then (a) this Agreement shall be construed as if drafted jointly by the Parties and (b) no provision shall be construed more severely against any Party.
Without limiting the generality of the preceding sentence, no presumption or burden of proof shall arise or apply favoring or disfavoring any Party by virtue of the authorship of any one or more provisions of this Agreement.

 10.17 Rights and Remedies. 
 Except to the extent provided in this Agreement, all rights and remedies of any Party shall be independent and cumulative and may be exercised concurrently or separately. The 

  

 - 16 - 

 
exercise of any one right or remedy by a Party shall not constitute an election of such right or remedy or preclude or waive the exercise of any other
right or remedy by a Party. 
 10.18 Representations. 
 Each Party represents and warrants to the other Party that its execution, delivery and performance of this Agreement
shall not breach or otherwise conflict with any contract to which they are a Party, subject or bound. 
 10.19
Attorney Review. 
 Each Party acknowledges and agrees that it has had the opportunity to consult with an attorney of
its choosing and has consulted with such attorney in connection with this Agreement or knowingly and voluntarily declined to do so. 
 10.20 Counterparts. 
 This Agreement may be executed in two or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 [Remainder of this page is blank.
Signature page follows.] 
  

 - 17 - 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be
duly executed on the dates written below. 
  

									
	 MIMEDX, INC.
	 		 	 OFFRAY SPECIALTY NARROW
 FABRICS, INC.

					
	 By:
	 	 /s/ M. G. Steele
	 		 	 By:
	 	 /s/ Denise A. Offray

					
	 Name:
	 	 Maria Geeneve Steele
	 		 	 Name:
	 	 Denise A. Offray

					
	 Title:
	 	 Senior Vice President
	 		 	 Title:
	 	 Chief Operating Officer

					
	 Date:
	 	 October 18, 2007
	 		 	 Date:
	 	 October 12, 2007

  

 - 18 -Collaborative Research and Evaluation Agreement

 Page 1 
  

 EXHIBIT 10.31 
 COLLABORATIVE RESEARCH AND EVALUATION AGREEMENT 
 This Collaborative Research
and Evaluation Agreement (“Agreement”), effective on the date the last Party executes this Agreement (“Effective Date”), is by and between MiMedx, Inc., a Florida corporation having its principal address at 1234 Airport Rd.,
Suite 105, Destin, FL 32541 (“MIMEDX”), and Regeneration Technologies, Inc., a Delaware corporation having its principal address at 11621 Research Circle, Alachua, FL 32615 (“RTI”). As used herein, RTI and MIMEDX may be referred
to collectively as “the Parties” or individually as a “Party.” 
 WHEREAS, MIMEDX holds an
exclusive, worldwide license with Shriners Hospitals for Children and the University of South Florida Research Foundation for intellectual property covering the polymerization chemistry of NDGA as applied to biological materials, bioprostheses, or
devices created through its application, as defined in United States Patent Nos. 6,565,960, 6,821,530, and other pending applications; 
 WHEREAS, RTI is a processor of orthopedic and other biologic matrix surgical implants, and has experience in, and certain proprietary technology related to, the generation and characterization of efficacious
and safe in-vivo applications of biomaterials for the repair and natural healing of human bone and other human tissues; 
 WHEREAS, RTI and MIMEDX previously executed a Mutual Confidentiality and Nondisclosure Agreement having an effective date of June 22, 2007; 
 WHEREAS, RTI and MIMEDX anticipate that this Agreement will allow them to jointly determine the feasibility of creating a commercially viable methodology for combining MIMEDX’s NDGA
technology with RTI’s biological matrix surgical implants and cleaning and sterilization technologies; and 
 WHEREAS, it is the intent of RTI and MIMEDX that the work performed as a result of this Agreement, and any intellectual property derived therefrom, shall be afforded the prior art protections provided for by the CREATE Act of 2004,
as codified by 35 USC 103 (c). 
 NOW, THEREFORE, in view of the foregoing premises, and in consideration of the
mutual covenants, terms and conditions hereinafter set forth, the Parties hereto agree as follows: 
 1. Definitions 
 1.1 “MIMEDX” Technology” shall mean patents, patent applications, know-how, trade secrets, and all technology owned,
controlled, or licensed by MIMEDX as of the Effective Date or thereafter during the Term of this Agreement, that relates specifically to biomaterials for soft tissue repair, such as tendons, ligaments and cartilage, as well as the production of
polymerized collagen for medical and/or surgical use, devices and/or components, including, but not limited to, the polymerization chemistry of NDGA as applied to biological materials, bioprostheses, or devices created through its application. This
includes, but is not necessarily 

 Page 2 
  

 
limited to, the technology as covered in US patents 6,565,960 and 6,821,530 and all immediate extensions thereof, past, present and future. 
 1.2 “RTI Technology/Biomaterials” shall mean patents, patent applications, know-how, trade secrets and all technology
owned, controlled, or licensed by RTI as of the Effective Date or thereafter during the Term of this Agreement, that relates specifically to RTI Biomaterials, specifically including RTI’s proprietary allograft, xenograft and biological matrix
technologies, cleansing, sterilization, packaging and distribution of RTI proprietary allograft, xenograft and biological matrix implants, as well as technology useful in manufacturing, and clinical and other uses of RTI Biomaterials. 
 1.3 “Project Technology” shall mean every technology, material, process, device, or article of manufacture which is
newly discovered, developed, made, perfected, improved, designed, engineered, devised, acquired, produced, conceived, or first reduced to practice by MIMEDX and/or RTI or any of their employees or agents in the course of performing their obligations
hereunder, whether tangible or intangible, including without limitation each and every invention, work of authorship, trade secret, formula, process, routine, subroutine, technique, concept, method, idea and algorithm, and all software and related
documentation in any source of development (including but not limited to source code, objects code, flow charts, diagrams and other materials of any type whatsoever) and all rights of any kind in or to any of the foregoing (including without
limitation copyrights, trade secret rights and patent rights) regardless of whether any or all of the foregoing constitutes copyrightable or patentable subject matter. 
 1.4 “Confidential Information” shall be given the meaning as defined in Article 4, below. Unless expressly stated to the contrary, or as may be otherwise clearly gleaned from the
context, the term “Confidential Information” as used throughout this Agreement shall be deemed to include information as to trade secrets that have been designated as “Confidential ad infinitum,” as defined in
Section 4.3, below. 
 1.5 “Protocol” shall mean a detailed scientific plan to explore the feasibility
of the synergistic combination of RTI Technology/Biomaterials and MIMEDX Technology (as outlined in the Statement Of Work, attached hereto and incorporated by reference as Exhibit A). 
 1.6 “Project” shall mean the research, experimentation and evaluation performed and to be performed by RTI and MIMEDX
pursuant to this Agreement as outlined in Exhibit A to determine the feasibility of using the MIMEDX Technology to enhance RTI’s Biomaterials for use in healthcare settings, to determine the feasibility of using the RTI Technology to
enhance MIMEDX Biomaterials for use in healthcare settings, and/or to facilitate the use of MIMEDX Technology in healthcare settings. 
 1.7 “Project Results” shall mean all tangible outputs produced in relation to the Project, including Project Technology, data, results or any other information generated or 

 Page 3 
  

 
developed by either RTI or MIMEDX, or their respective employees, agents or consultants, in conducting the Project. 
 2. Description of the Project 
 2.1 Work to be Performed by RTI and MIMEDX. RTI and MIMEDX shall perform the work contemplated by the Project in accordance with the desired project characteristics and guidelines set forth in Exhibit A. 
 2.2 Description of Research and Evaluation Procedures 
 2.2.1 The Project described in the Statement of Work, Exhibit A, shall be conducted by both Parties as a collaborative effort under the direction of the Project Managers, to be
appointed as set forth in Section 5.1. 
 2.2.2 Both Parties shall provide scientific personnel and technical
expertise to carry out the Project. Both Parties shall bear their own expenses associated with the scientific personnel and technical expertise it provides, as further described in Exhibit A. 
 2.2.3 To the extent necessary to carry out the collaborative research and evaluation contemplated by the Project, or as may be
necessary to obtain governmental and regulatory approvals for Protocols, the Parties shall exchange all necessary technical information, including all preclinical and clinical information, and shall provide all necessary technical assistance and
training to the other. All information transferred, provided or exchanged under this Section 2.2.3 shall be subject to the confidentiality requirements set forth in Article 4. 
 2.2.4 Each Party agrees to make its employees and non-employee consultants reasonably available at their respective places of
employment to consult with the other Party on issues arising during the Project and in connection with any request from any regulatory agency, including, without limitation, regulatory, scientific, technical and clinical testing issues. 

2.2.5 Representatives of RTI and MIMEDX may, upon reasonable notice and at times reasonably acceptable to the other Party
(a) visit the facilities where the Project is being conducted and (b) consult informally with personnel of the other Party performing work on the Project during such visits, by telephone, by facsimile or electronic transmission, or in any
other manner as the Parties shall agree. If requested by the other Party, RTI and MIMEDX shall cause appropriate individuals working on the Project to be available for meetings at the location of the facilities where such individuals are employed at
times reasonably convenient to the Party responding to such request. 
 2.2.6 RTI and MIMEDX shall each maintain
records in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes and as will properly reflect all work done and results achieved in the performance of the Project (including all data in the form required
under any applicable governmental regulations). RTI and MIMEDX shall each provide the other the right to inspect and copy all such records to the extent reasonably required 

 Page 4 
  

 
for the performance of its obligations under this Agreement; provided that each Party shall maintain such records and the information of the other contained
therein in confidence in accordance with Article 4 below and shall not use such records or information except to the extent otherwise permitted by this Agreement. 
 2.3 Exclusivity of Research Engagement. 
 2.3.1 Allograft
Tissue. During the term of this Agreement, the Parties agree that they will not engage in research or collaborative efforts with non-parties on matters involving: (i) NDGA treatment of musculoskeletal allograft tissue constructs, whether
with or without combination with MiMedx collagen fibers. 
 2.3.1.1 For purposes of Section 2.3.1.1,
“musculoskeletal allograft tissue constructs” means (i) substantially intact or minimally manipulated allograft tissue implants comprising bone, muscle, fascia, cartilage, ligaments, tendons, and/or menisci, and (ii) biological
matrices containing demineralized bone matrix “DBM.” The Parties recognize and agree that sterilization and/or aseptic processing of musculoskeletal allograft tissue constructs is essential to the creation of safe implants. As such,
sterilization and/or aseptic processing of musculoskeletal allograft tissue shall not, by itself, be deemed manipulation of the allograft tissue. 
 2.3.2 This exclusivity provision does not apply to any other NDGA collagen fiber constructs and shall not be interpreted to include stand-alone NDGA fibers that are not in combination with either allograft
tissue constructs as defined above. 
 3. Deliverables 
 The Deliverables under this Agreement are set forth in Exhibit A. 
 4.
Confidential Information 
 4.1 MIMEDX Confidential Information. With respect to MIMEDX, the term
“Confidential Information” refers to its specialized and proprietary trade secrets, formulas, processes, methods, technology, know-how, customer and vendor information and lists, financial data, undisclosed and unreleased products, and
other items or information related to its xenograft tissue, surgical implants, collagen for human implants, NDGA-polymerized collagen technology and any laboratory and clinical testing and research methodologies or models that when furnished, shown,
or disclosed to RTI is designated, whether in writing or orally (followed by a written confirmation and summary) as “Confidential,” or which is of such nature and character that a reasonable person in the trade would understand it to be
confidential without the necessity of it being so designated. All Confidential Information disclosed by MIMEDX, except for jointly owned Confidential Information as set forth in Section 4.4, shall remain the exclusive property of MIMEDX.

 4.2 RTI Confidential Information. With respect to RTI, the term “Confidential Information” refers to its
specialized and proprietary trade secrets, formulas, processes, methods, 

 Page 5 
  

 
technology, know-how, customer and vendor information and lists, financial data, undisclosed and unreleased tissue lines or products, and other items or
information related to its allograft tissue, xenograft tissue, surgical implants, collagen for human implants, associated processing and sterilization technologies for each, and any laboratory and clinical testing and research methodologies or
models that when furnished, shown, or disclosed to MIMEDX is designated, whether in writing or orally (followed by a written confirmation and summary), as “Confidential,” or which is of such nature and character that a reasonable person in
the trade would understand it to be confidential without the necessity of it being so designated. All Confidential Information disclosed by RTI, except for jointly owned Confidential Information as set forth in Section 4.4, shall remain the
exclusive property of RTI. 
 4.3 Confidential ad infinitum. The Parties recognize and agree that the
other Party may possess certain trade secrets that will likely continue to have commercial and competitive value for an indeterminate period of time, and perhaps in perpetuity. Therefore, a Party may in its sole discretion designate as
“Confidential ad infinitum” those certain trade secrets it reasonably believes fit such criteria. Any provision of this Agreement to the contrary not withstanding, trade secrets must be designated orally or in writing as
“Confidential ad infinitum” at the time of disclosure. In the event of an oral designation, the disclosing Party must confirm the designation in writing to the receiving Party within one (1) week following disclosure. Trade
secrets that are Confidential ad infinitum shall at a minimum be given all the same protections as Confidential Information, with certain added or heightened requirements as further described below. Election not to designate a trade secret as
Confidential ad infinitum, or failure to so designate, shall not be deemed to erode or abrogate a trade secret’s underlying status as Confidential Information. 
 4.4 Jointly Owned Confidential Information. With respect to this Agreement, the Project Results, negotiations between the Parties, financial and prospective financial data, and any other
information jointly generated by the Parties as a result of this Agreement, including the existence of this Agreement and the fact that a relationship between the Parties exists, shall be “Confidential Information” jointly owned by the
Parties. Subject to Sections 4.4 and 4.7 and except for the use of Joint Inventions under Section 8.2.2, a Party wishing to disclose any part of this jointly owned Confidential Information must first obtain written permission from the other
Party by contacting the designated corporate representative for such purpose as set forth in Section 4.7. 
 4.5
Protection of Confidential Information. To the maximum extent permitted by applicable law, and except as otherwise expressly permitted pursuant to any other provision of this Agreement, RTI and MIMEDX, their employees and consultants, agree to
observe complete confidentiality with regard to the Confidential Information; not to disclose or otherwise permit any third parson or entity access to the Confidential Information or any portion thereof without the other Party’s prior written
permission (except that such disclosure or access shall be permitted to an employee of the Party to the extent required by such employee in order to perform duties consistent with the terms of this Agreement, so long as the disclosure is not
inconsistent with, where applicable, Section 4.5.1); to ensure that the Party’s employees who 

 Page 6 
  

 
receive access to the Confidential Information or any portion thereof are advised of the confidential and proprietary nature of the Confidential Information
and to ensure by agreement pursuant to Section 4.7 hereof that they are prohibited from copying or revealing, for any purpose whatsoever, the Confidential Information (or any part thereof) or from taking any action prohibited under this
Agreement (except that such copying or revealing shall be permitted to an employee to the extent required by such employee in order to perform duties not inconsistent with the terms of this Agreement); to notify the other Party promptly and in
writing of any circumstances relating to any possession or use of the Confidential Information (or any part thereof) by any person or entity other than those authorized under this Section 4.5; and to take any and all other actions reasonably
deemed necessary or appropriate by the other Party from time to time to ensure the continued confidentiality and protection of the Confidential Information. 
 4.5.1 Protection of Information Designated as Confidential ad infinitum. All protection provided to Confidential Information under Section 4.5 shall apply to trade
secrets that have been designed as Confidential ad infinitum, with the following additional items and limitations: (i) in advance of disclosure to an employee or consultant (hereinafter “Employee”) of the receiving Party, and
regardless of whether disclosure has already been made to another Employee of the receiving Party, the receiving Party shall identify to the disclosing Party the Employee it wishes to receive the trade secret information; (ii) the disclosing
Party may in its sole discretion approve or disapprove of the receiving Party’s selected Employee; (iii) the receiving Party’s act of identifying the aforementioned selected Employee to the disclosing Party serves as an express and/or
implied warranty by the receiving Party that it has an existing confidentiality agreement in place with the selected Employee; and (iv) the disclosing Party may in its sole discretion require a separate agreement between it and the receiving
Party’s Employee confirming that said Employee has read and agrees to be bound by the provisions of this Agreement pertaining to the protection of information that is Confidential and Confidential ad infinitum. To the extent any part of
this Section 4.5.1 may be inconsistent or deemed to conflict with any other portion of this Agreement, the terms of this Section 4.5.1 shall control. 
 4.6 Survival; Remedies. The obligations and rights of the Parties under this Article 4 shall survive any expiration or termination of this Agreement for any reason whatsoever (including,
without limitation, termination by either Party for a material breach by the other Party of its obligations hereunder) for, in the case of Confidential Information, a period of five (5) years, or, in the case of trade secrets that are
Confidential ad infinitum, for an initial period of ten (10) years with options to renew the Confidential ad infinitum designation for additional terms of five (5) years for as long as the disclosing Party reasonably and in
good faith believes such continuing status is competitively advantageous. The disclosing Party must submit thirty (30) day advance written notice of its intent to renew the Confidential ad infinitum designation. Because of the unique and
proprietary nature of the information that is Confidential and/or Confidential ad infinitum, it is understood and agreed that either Party’s remedies at law for a breach by the other Party of its obligations under this Article 4 will be
inadequate and that the non-breaching Party shall, in the event of any such breach, be entitled to equitable relief (including without limitation injunctive relief and specific performance) without any requirement 

 Page 7 
  

 
to post a bond as condition for such relief, in addition to all other remedies provided under this Agreement or available at law. 
 4.7 Publication. Neither Party shall disclose, publish, communicate, or reveal the other Party’s Confidential Information to
any third party, person, corporation or business entity, or the employees thereof, without the express prior written permission from the disclosing Party, and only after such other third party, person, corporation or business entity executes a copy
of this Agreement or a similar agreement consented to by the disclosing Party. The Parties further agree that, except as required by applicable law or a court of competent jurisdiction, the Parties and each of its directors, officers, employees,
agents, and representatives will not disclose (publicly or to any third party) the terms or existence of this Agreement without first obtaining written consent from the other Party, which shall not be unreasonably withheld. The Party seeking consent
shall direct its inquiry to the other Party’s applicable contact at: 
  

									
	 Maria Steele
	  		  		  	 Wendy Crites-Wacker, APR
	  	
	 Senior Vice President
	  		  		  	 Director of Corporate Communications
	  	
	 MiMedx, Inc.
	  		  		  	 Regeneration Technologies, Inc.
	  	
	 1234 Airport Rd.
	  	or	  		  	 11621 Research Circle
	  	
	 Suite 105
	  		  		  	 Alachua, FL 32615
	  	
	 Destin, FL 32541
	  		  		  		  	

 4.8 Obligations. Each Party agrees not to use the Confidential Information
of the other Party, including Jointly Owned Confidential Information, for any purpose except for the purposes described above and as necessary to carry out the terms of any business relationship between the Parties hereto. Each Party further agrees
that it will not disclose Confidential Information of the other Party to any person other than its employees, agents or consultants who are directly involved in the business relationship between the Parties hereto, and only on a need-to-know basis.
In the event the enhanced obligations of Sections 4.5.1 and 4.6 are applicable, those enhanced obligations shall also apply. Each Party agrees that it will take reasonable security measures and use reasonable care to preserve and protect the secrecy
of the other Party’s Confidential Information. 
 4.9 Return of Information. Upon request by the disclosing
Party, the recipient shall promptly return to the disclosing Party within ten (10) business days all written or tangible material containing or reflecting Confidential Information of the disclosing Party (whether prepared by the disclosing
Party or otherwise), without retaining any copies, summaries, analyses, or abstracts thereof except that each Party’s independent outside counsel may retain one copy for attorney’s eyes only. 
 4.10 No Grant or Right or License. Except as expressly set forth in this Agreement, nothing in this Agreement shall be construed
as granting any right, title, interest or license in the Confidential Information of the disclosing Party to the receiving Party or any other person or entity, by implication or otherwise. 

 Page 8 
  

 4.11 Mandatory Disclosures. When Confidential Information is required to be
disclosed by the receiving Party to comply with applicable laws or regulations, or with a court or administrative order, the receiving Party shall (i) provide to the disclosing Party, to the extent reasonably practicable, prior written notice
of such mandated disclosure and, upon request by the disclosing Party, (ii) provide the disclosing Party, to the extent reasonably practicable, assistance with taking all reasonable and lawful actions to obtain confidential treatment for the
Confidential Information, and (iii) take all reasonable and practicable steps to minimize the extent of such disclosure. 
 4.12 Safe Harbor. The provisions of this Article 4 will not apply to information which the receiving Party can affirmatively show: 
  

	 	(a)	 was independently developed or discovered by the receiving Party without use or benefit of the disclosing Party’s Confidential Information, as demonstrated
by the receiving Party’s written records; 

  

	 	(b)	 is already available to the public; 

  

	 	(c)	 becomes available to the public through no fault of the receiving Party; or 

  

	 	(d)	 is independently developed by an employee or consultant of the receiving Party who had no previous direct or indirect knowledge or benefit of the disclosures
made under this Agreement. 

 5. Review Meetings and Monitoring of Project 
 5.1 Project Managers. RTI and MIMEDX shall each designate in writing within ten (10) days of the Effective Date one or more
individuals to serve as its project manager(s) with respect to the Project (the “Project Manager”). The role of the Project Manager(s) for each Party shall be as follows: 
  

	 	(a)	 coordinate the collaborative research efforts for their respective Party; 

  

	 	(b)	 regularly review the Protocol and scientific objectives of the collaboration; 

  

	 	(c)	 periodically review the goals and strategy of the collaboration; 

  

	 	(d)	 facilitate the exchange of information between the Parties; 

  

	 	(e)	 receive and review deliverables under the Protocol; 

  

	 	(f)	 assist with the review of proposed publications related to the results of the collaboration; 

 Page 9 
  

	 	(g)	 review and allocate necessary resources, as well as determining the number and full-time-equivalent (FTE) scientists and laboratory or other support personnel
that may be needed for the collaboration; 

  

	 	(h)	 serve as a liaison between the research team and the respective organizations; 

  

	 	(i)	 assist with determining the milestones in the collaborative process have been met to the satisfaction of their respective organizations; and

  

	 	(j)	 serve as the contact point through which intellectual property developed as a result of work performed under this Agreement is routed.

 In the event either Party’s Project Manager leaves the employ of such Party, is reassigned or is
unable or unwilling to perform his or her duties, he or she shall be replaced within ten (10) business days. 
 5.2
Progress Meetings and Reports. Once every month during the term of the Project (or more or less frequently as the Parties shall mutually agree in writing) the MIMEDX Project Manager shall meet with the RTI Project Manager via teleconferences or
at a mutually agreed upon location to discuss the progress made by MIMEDX and RTI in the performance of their obligations under this Agreement during the preceding month. At such meeting, each Project Manager shall prepare and submit to the other
Project Manager a written report summarizing the current status of the Project and the progress to date. Such report shall follow a format to be reasonably agreed upon between RTI and MIMEDX, but in any event shall specify in detail the following:

  

	 	(a)	 a listing of any milestones met, deliverables achieved, or results found during the prior month; and 

  

	 	(b)	 any issue or circumstance encountered, or of which the Party first learns, during the prior month that may prevent or tend to prevent the Party from completing
any part of the Project within the time frame estimated in Exhibit A (Statement of Work); and 

  

	 	(c)	 the estimated length of delay which may result from any such issues identified pursuant to subparagraph (a) above; and 

  

	 	(d)	 to the best of the Party’s knowledge the cause of any such issue and the specific steps taken or proposed to be taken by the Party to address any such
issue. 

 Each Party shall bear all of its own costs associated with preparing for and attending such
meetings. 

 Page 10 
  

 5.3 Technical Meetings. Technical meetings shall be held during the Term of this
Agreement as may be necessary for the Parties to discharge their technical responsibilities hereunder. Technical meetings may be conducted by telephone, facsimile transmission or in any other manner as the Parties shall agree. Technical meetings
will address reports, coordinate the tasks and the activities required to fulfill the Project objectives, monitor the progress of the Project toward those objectives, and set priorities for further work. 
 6. Costs. Except as specified in Section 6.1, below, each Party shall bear its own costs related to its operations and general functioning as
a business entity, including, but not limited to, obtaining, reinstating, or maintaining all regulatory approvals and licenses. 
 6.1 Costs related to the performance of this Agreement shall be borne by the respective Parties in accordance with the breakdowns of workload as set forth in Exhibit A. 
 6.2 In addition to those items applicable to RTI as described in Section 6.1, above, RTI shall direct under its discretion
the prosecution of, and shall advance the costs for, obtaining domestic and/or international intellectual property protection on Joint Inventions for which the Parties have mutually agreed to seek said protection, including attorneys’ fees,
costs, and maintenance fees (“IP Costs”). Subject to Section 8.2.1, RTI shall allow MIMEDX to substantively participate on the content and filing strategy of such intellectual property protection. RTI shall use patent counsel mutually
agreeable to the Parties. MIMEDX shall refund half of the reasonable IP Costs, offset by its own attorney fees for IP Costs for Joint Inventions that it mutually agrees to seek or maintain, upon written request with a copy of the invoice evidencing
such reasonable costs, with reimbursement being due and payable thirty (30) days from the date of invoice. 
 6.3
In the event the Parties do not mutually agree to seek or maintain, or continue to seek or maintain, intellectual property protection for a Joint Invention, the non-objecting Party may choose to pursue intellectual property protection at its own
discretion and cost. The objecting Party shall cooperate with executing documents reasonably required by the non-objecting Party in its effort to obtain intellectual property protection. 
 7. Term of Agreement. The Parties agree to commence the Project upon the Effective Date. This Agreement will expires twelve (12) months from the Effective Date, with the option to
extend the Agreement thereafter as mutually agreed to in writing by the Parties. 
 7.1 Termination. Either Party can
terminate the Agreement for any reason upon one hundred eighty (180) days written notice to the other Party. 
 7.2
Effect of Termination or Expiration 
 7.2.1 Upon termination or expiration of this Agreement, neither Party shall
have any further right to commercially practice the other Party’s Confidential Information. 

 Page 11 
  

 7.2.2 Within ten (10) days following the expiration or termination of this
Agreement, each Party shall return to the other Party, or destroy, upon the written request of the other Party, any and all Confidential Information of the other Party in its possession and upon a Party’s request, except that each Party’s
legal counsel may retain one (1) copy of the Confidential Material. The destruction (or delivery) of the other Party’s Confidential Information shall be confirmed in writing to such Party by a responsible officer of the other Party.

 7.2.3 The rights, responsibilities and obligations of Articles 4 and 8 shall survive termination or expiration of
this Agreement. 
 8. Ownership and Use of Inventions. The Parties hereby agree that, in the event inventions are conceived and first
reduced to practice during the performance of the research conducted under this Agreement (“Inventions”), the inventorship, and the ownership of such inventions, shall be as follows: 
  

	 	(a)	 ownership shall be determined by inventorship; 

  

	 	(b)	 inventorship shall be determined in accordance with U.S. Patent Laws; 

  

	 	(c)	 for the proper determination of inventorship, the Parties shall fully and promptly disclose, in confidence, any and all Inventions resulting directly from the
Project or directly related to the Project Technology in writing to the other Party. 

 8.1 Sole
Inventions. Inventions made entirely by employees of one Party during the performance of the research conducted under this Agreement (“Sole Inventions”) shall be the exclusive property of the inventing Party, and shall be handled in
accordance to the internal policy of that Party, subject to Sections 8.1.1 and 8.1.2, below. Patent protection shall be at the sole discretion and control of the inventing Party. 
 8.1.1 License. The inventing Party agrees to grant to the non-Inventing Party a non-exclusive, royalty-free, non-commercial license
to Sole Inventions for internal research purposes. 
 8.1.2 Right of First Refusal. If patent protection is sought for
the Sole Invention(s), the non-inventing Party shall have a right of first refusal to license the Sole Invention on mutually agreeable terms. Unless extended by mutual written agreement, the Parties shall have six (6) months from the date on
which negotiations were first initiated (the “Negotiation Term”) to execute a license agreement, failing which the inventing Party may then pursue negotiating a license agreement with a non-Party, subject to Section 8.1.2(b). Subject
to the right to exclude others found in other blocking patents of the inventing Party, if patent protection is not sought for a Sole Invention, the inventing Party agrees that the non-inventing Party shall be free to commercially practice and/or
allow others to practice the Sole Invention(s) without further approval or accounting to the inventing Party. 

 Page 12 
  

 8.1.2(a) Negotiation Term. The Parties agree that definitively establishing a
date on which negotiations are initiated for purposes of Section 8.1.2, above, is essential to promoting cooperation and reducing confusion between the Parties. Therefore, the Negotiation Term shall be formally initiated in writing from the
inventing Party to the non-inventing Party via overnight courier to the appropriate addresses as given in Section 11.2, below. The first day of the Negotiation Term will be established as the date on which the writing was deposited with the
overnight courier, as established by the courier’s bill of lading or, in the case of the United States Postal Service, the postmark. 
 8.1.2(b) Most Favored Party. For a period of seven (7) years as measured from the end of the Negotiation Term, or from the end of the termination or expiration of the Agreement, whichever is longer, the
inventing Party agrees not to license the Sole Invention, if patent protection has been sought on the Sole Invention, to a non-party without first providing the non-inventing Party with an opportunity to match the inventing Party’s terms with
the non-party. The non-inventing Party will have ten (10) business days from the date it is first notified of the terms between the inventing Party and non-party during which to accept or reject the terms. 
 8.2 Joint Inventions. Inventions made by employees of both Parties shall be deemed to be joint property to such Parties
(“Joint Inventions”), each such Party having an undivided equal interest in the same. 
 8.2.1 Patent Protection
of Joint Inventions. Subject to Section 6.1, the Parties agree to consult with one another prior to taking any action to obtain patent protection of Joint Inventions and shall agree upon the patent filing and prosecution strategy of said
Invention. Each party agrees to cooperate in timely completion and execution of all documents or other items necessary to further the domestic and/or international intellectual property protection available to the Joint Inventions. 
 8.2.2 Use of Joint Inventions. The Parties agree to engage in good faith negotiations directed toward entering into an exclusive
license for one of the Parties to commercially exploit a subject Joint Invention if patent protection is being sought for that Joint Invention. The Parties shall have one (1) year from the date of filing (extendable by mutual written agreement
of both Parties) of a utility patent application (whether foreign or domestic), by which to negotiate an exclusive license for use of the Joint Invention. In the event the Parties fail to reach an agreement within the prescribed time frame, the
Parties may then pursue utilizing the Joint Invention within their legal rights, provided, however, that within said prescribed time frame and for a period of seven (7) years from the end of said prescribed time frame the Parties each agree not
to license the Joint Invention to a non-party without first providing the other Party with an opportunity to match the agreed upon terms with the non-party. The Party will have ten (10) business days from the date it is first notified of the
proposed terms between the other Party and non-party during which to accept or reject the terms. 

 Page 13 
  

 Subject to the right to exclude others found in other blocking patents or an inventing
Party, if patent protection is not sought for a Joint Invention, the Parties shall be free to commercially practice and/or allow others to practice the Joint Invention(s) without further approval or accounting. 
 8.3 Prior Inventions. Nothing contained in this Agreement shall be deemed to grant either Party, directly or by implication,
estoppel, or otherwise, any right, title, interest or license to any patents, patent applications, copyrights, trademarks, mask works, trade secrets or other intellectual property owned or developed by the other Party either before or independent of
this Agreement. 
 9. No Third-Party Rights. Each Party warrants, represents and agrees that no person or entity employed to aid in
the performance of the Party’s obligations hereunder shall have any right of any kind to the Project Results. The Parties warrant, represent and agree that they have obtained or will obtain from any person or entity rendering services in
connection with the conduct of the research and experimentation hereunder a written assignment agreement which provides (i) that such person or entity does not have a conflict of interest and will take appropriate steps to avoid conflicts in
the future; (ii) that all right, title and interest in and to any portion of the research and experimentation contributed or created by such person, including copyright, shall belong exclusively to the Party; and (iii) that any portion of
the research and experimentation contributed or created by such person or entity shall not knowingly infringe or invade the copyright, patent, trade secret or other proprietary rights of any third party. 
 10. Insurance. 
 The
Parties will obtain and maintain comprehensive general liability insurance with minimum limits of general and professional liability insurance for $1,000,000 / $3,000,000, respectively, per incident and aggregate. The Parties shall provide, or shall
cause their insurance provider to provide, a certificate of insurance to the other Party upon request. 
 11. Miscellaneous.

 11.1 Remedies Cumulative. Except as specifically provided herein, no remedy made available to either Party
hereunder is intended to be exclusive of any other remedy, and each and every remedy shall be cumulative and shall be in addition to every other remedy provided hereunder or available at law or in equity. 
 11.2 Notices. Any notice, report, or consent required or permitted by this Agreement to be given or delivered, shall be in writing
and shall be deemed given or delivered if delivered in person, sent by courier, expedited delivery service, registered or certified mail, postage prepaid, return receipt requested, or by telecopy (if confirmed), as follows: 

 Page 14 
  

							
	 RTI
	  		  	 MIMEDX
	  	
				
	 Tom Rose
	  		  	 Maria Steele
	  	
	 CFO
	  		  	 Senior Vice President
	  	
	 Regeneration Technologies, Inc.
	  		  	 MiMedx, Inc.
	  	
	 11621 Research Circle
	  		  	 1234 Airport Rd., Suite 105
	  	
	 Post Office Boxes 2650
	  		  	 Destin, Florida 32541
	  	
	 Alachua, Florida 32616-2650
	  		  	 Fax: (850) 650-2213
	  	
	 Fax: (386) 462-3821
	  		  		  	
				
	 With a copy to:
	  		  	 With a copy to:
	  	
				
	 Corporate Counsel
	  		  	 J. Richardson, Esq.
	  	
	 Regeneration Technologies, Inc.
	  		  	 Myers, Bigel, Sibley & Sajovec, P.A.

	 11621 Research Circle
	  		  	 4140 Parklake, Ave.
	  	
	 Post Office Box 2650
	  		  	 Suite 600
	  	
	 Alachua, FL 32616-2650
	  		  	 Raleigh, NC 27627
	  	
	 Fax: (386) 462-1836
	  		  	 Fax: (914) 854-1401
	  	

 11.3 Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same agreement. 
 11.4 Waivers. Performance of any obligations required of a Party hereunder may be waived only by a written waiver signed by the other Party, which waiver shall be effective only with respect to the specific obligations described
therein. 
 11.5 Assignment. Neither Party may assign this Agreement or any of its rights or obligations hereunder
(including without limitation rights and duties of performance) to any third party, and this Agreement may not be involuntarily assigned or assigned by operation of law, without the prior written consent of the other Party hereto, which consent
shall not be unreasonably withheld. Notwithstanding the foregoing, this Agreement and the rights, interests and obligations hereunder may be assigned by RTI or MIMEDX (the “Assignor”) to any entity (i) which owns all of the
Assignor’s issued and outstanding voting stock, (ii) of which Assignor owns all of the issued and outstanding voting stock, (iii) which acquires substantially all of Assignor’s operating assets or (iv) into which Assignor is
merged or reorganized pursuant to any plan of merger or reorganization; provided, however, that notwithstanding any such assignment, Assignor shall remain liable for the performance of all of its obligations hereunder. 
 11.6 Entire Agreement; Amendments. This Agreement constitutes the entire agreement between the Parties with respect to the subject
matter hereof, and supersedes and cancels all prior agreements, communications and understandings, whether written or oral. This agreement may not be modified or amended except by an instrument in writing signed by both of the Parties hereto.

 Page 15 
  

 11.7 Severability. Should any part or provision of this Agreement be found invalid
or held unenforceable, the remainder shall remain valid and in full force. The Parties agree to negotiate in good faith amendment of such part or provision in a manner consistent with the intention of the Parties as expressed in this Agreement.

 11.8 Independent Contractors. Nothing contained in this Agreement shall be construed as creating a joint venture,
partnership or employment relationship between the Parties hereto. Except as specified herein, neither Party shall have the right, power or implied authority to create any obligation or duty, express or implied, on behalf of the other Party hereto.

 11.9 Governing Law. This Agreement shall be construed and enforced in accordance with the laws of Florida.

 11.10 Indemnification. Except as otherwise expressly provided herein, each Party agrees to indemnify and hold the
other harmless from and against any and all claims, demands, loss, damage or costs (including attorneys’ fees) arising out of or incurred in connection with any claim by a third Party which is inconsistent with or in breach of any of the
covenants, warranties or representations made by the indemnifying Party hereunder. 
 11.11 Dispute Resolution. In
case any dispute shall arise with respect to matters which cannot be resolved within a reasonable period of time, the Chief Executive Officers shall meet to attempt to resolve the matter prior to either Party taking any legal or other action in
respect thereof. If the Chief Executive Officers are unable to resolve any such dispute, such dispute shall be settled pursuant to final and binding arbitration administered by the American Arbitration Association, conducted by a panel of three
(3) arbitrators (consisting of one arbitrator selected by each of the Parties and agreed to by the other Party, and a third arbitrator selected by the other arbitrators who will act as chair of the proceedings) in the State of Florida and
judgment upon the award may be entered in any court having jurisdiction thereof. For purposes of clarification, the Parties agree neither to initiate nor to reopen any disputed matter in a court proceeding following arbitration buy may use the
assistance of the courts only to enforce any arbitration award. The Parties shall equally share the out-of-pocket costs of said arbitration, including the fees for the arbitrator, except that each Party shall pay its respective expenses for legal
representation and expert witnesses, if any. 
 [SIGNATURE PAGE FOLLOWS] 

 Page 16 
  

 IN WITNESS WHEREOF, this Agreement has been executed by the Parties hereto as of the date
first above written. 
  

									
	 Regeneration Technologies, Inc.
	 		 	 MiMedx, Inc.

					
	 By:
	 	 /s/ Thomas F. Rose
	 		 	By:	 	 /s/ M. G. Steele

		 	      Thomas F. Rose, CFO
	 		 		 	         Maria Steele, Sr. VP

					
		 	 10/31/07
	 		 		 	 11/01/07

		 	     Date
	 		 		 	         (Effective Date)

 Page 17 
  

 EXHIBIT A 
 Collaborative Research and Evaluation Plan: 
 MiMedx and Regeneration Technologies 

Statement Of Work 
 This is a Statement of Work for the Collaborative Research and Evaluation Agreement (“Agreement”) between Regeneration Technologies, Inc. (RTI) and MiMedx, Inc. (MiMedx). There are two
main goals of this research collaboration. This first research goal will focus on the effects of NDGA cross-linking of certain human tissue forms. Evaluation parameters for this goal would include biomechanics, biodegradability and biocompatibility.
The second research goal would focus on the effects of RTI’s BioCleanse® Tissue Sterilization process on the NDGA cross-linked extruded fibers in terms of sterility, biomechanics and
biocompatibility. Positive results from studies directed toward either goal could result in a number of final marketable graft or implant configurations. Future studies with additional research questions, or other aspects of NDGA crosslinking
technology, are outside the scope of this Statement of Work, unless amended by mutual written agreement of the Parties. 
 As outlined below
in the research plan, each Party is responsible for certain aspects of this work. The research plan also describes the deliverables expected from the resulting research. The scope of work for this Statement of Work and the Agreement to which it is
attached may be amended in accordance with the terms of the Agreement. Any further work beyond the scope of this Statement Of Work may require a joint Co-Development Agreement, or other type of agreement as may be dictated by the circumstances, to
be negotiated in good faith between the Parties at a later date. 
 Research Plan: 
  

	1)	 Effects of NDGA on Human Allograft Tissue Constructs: 

 Goal: To evaluate and develop a protocol for treating certain human tissue forms with NDGA. This is foundational work, prerequisite to any potential future development project which might
focus on developing marketable human cellular and tissue based products (HCT/P’s) or medical devices using the NDGA cross-linking technology together with RTI’s proprietary technology. 
 Scope: To obtain biomechanical, biodegradability and biocompatibility data on the use of NDGA cross-linking of whole human allograft tissue
constructs. Biomechanical measurements will consider standard RTI protocol with 1000 loading cycles and pull to failure. Stiffness, elongation during cycling, load and strain at failure will be estimated from stress-strain curves. Biodegradability
will be performed using standard collagenase digestion to determine % of digested collagen after exposure to enzyme. Biocompatibility will be assessed by implantation of crosslinked vs. non-crosslinked tissue subcutaneously in rat, and looking for
the extent and type of inflammatory response after 4 to 6 weeks. Both tendon and pericardium data would include in vitro and in vivo analyses. Possible other tissue forms of interest could include 

 Page 18 
  

 
crosslinked configurations of other collagenous scaffolds produced by RTI, e.g. collagen membranes, sponges or gels with or without added Demineralized Bone
Matrix (DBM). 
 Costs of Proposed Study: It is understood that each party will be responsible for their own costs incurred during
this study in accordance with the terms of the Agreement. RTI will be responsible for the costs of retrieving and shipping the cadaveric tissue to MiMedx. All costs associated with NDGA cross-linking of the human allograft tissue constructs will be
the responsibility of MiMedx. All costs associated with biomechanical testing and in vivo characterization in the rat subcutaneous implantation model will be the responsibility of RTI. Any remaining costs per task shall be the responsibility
of the party performing the task. 
 Breakdown of Workload: 
  

					
	 Task
	 	 RTI
	 	 MiMedx

	 Tissue retrieval from cadaveric material (human allograft tissue)
	 	X	 	
	 Shipment of tissue to MiMedx
	 	X	 	
	 NDGA cross-linking of tissues received
	 		 	X
	 Shipment of cross-linked tissues to RTI
	 		 	X
	 Biomechanical testing and analysis
	 	X	 	
	 Biocompatibility testing and analysis
	 	X	 	
	 Biodegradability testing and analysis
	 	X	 	

 Timelines: Work is expected to begin during November, 2007 and is expected to take about 6
to 9 months to complete. Each party agrees to use commercially reasonable efforts to advance the work. 
 Breakdown of Deliverables: 
  

					
	 Deliverable
	 	 RTI
	 	 MiMedx

	 Protocol for NDGA cross-linking of human allograft tissue constructs
	 		 	X
	 Report on results from in vitro assays
	 	X	 	X
	 Report on results from in vivo assays
	 	X	 	
	 Development plan for NDGA cross-linking of human allograft tissue constructs in orthopedic settings
	 	X	 	X

  

	2)	 Effects of BioCleanse on NDGA cross-linked extruded collagen fibers: 

 Goal: To create a protocol for BioCleanse® Tissue Sterilization Process treatment of NDGA cross-linked extruded collagen fibers. This is foundational work, prerequisite to any
potential future development project which might focus on developing marketable HCT/P’s or medical 

 Page 19 
  

 
devices using the NDGA cross-linking technology together with the BioCleanse® Tissue Sterilization Process. 
 Scope: To explore the potential of RTI’s existing BioCleanse® Tissue Sterilization Process to sterilize NDGA cross-linked extruded
collagen fibers and to obtain biomechanical and biocompatibility data on NDGA cross-linked extruded collagen fibers. Data would include in vitro and in vivo analyses. The in vivo studies would include subcutaneous implantation
into rats. 
 Costs of Proposed Study: It is understood that each party will be responsible for their own costs incurred during this
study in accordance with the Agreement. All costs associated with producing NDGA cross-linked collagen fibers will be the responsibility of MiMedx. All costs associated with the BioCleanse® Tissue Sterilization Process, as well as in
vitro and in vivo characterization in the rat subcutaneous implantation model will be the responsibility of RTI. Any remaining costs per task shall be the responsibility of the party performing the task. 
 Breakdown of Workload: 
  

					
	 Task
	 	 RTI
	 	 MiMedx

	 NDGA cross-linking of extruded fibers
	 		 	X
	 Shipment of NDGA cross-linked extruded fibers to RTI
	 		 	X
	 BioCleanse® processing of fibers
	 	X	 	
	 Biomechanical testing and analysis
	 		 	X
	 Biocompatibility testing and analysis
	 	X	 	

 Timelines: Work is expected to begin during November, 2007 and is expected to take about 6
to 9 months to complete. Each party agrees to use commercially reasonable efforts to advance the work. 
 Deliverables: 
  

					
	 Deliverable
	 	 RTI
	 	 MiMedx

	 Protocol for treating extruded fibers with BioCleanse process
	 	X	 	
	 Report on results from in vitro assays
	 	X	 	X
	 Report on results from in vivo assays
	 	X	 	
	 Development plan for BioCleanse treated extruded fibers for marketable products
	 	X	 	X

 To the extent any provision of this Exhibit A may conflict with the Agreement, the terms of the
Agreement will control.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}]]